NCT05989711
IMPACT — pemvidutide in MASH
Phase Phase 2
Status Recruiting
Indication MASH
Enrollment 200
Last updated:Jul 15, 2026Source:ClinicalTrials.govVerified:NCT ID verified against public registryData provider:ClinicalTrials.gov API v2
Overview
- NCT ID
- NCT05989711
- Phase
- Phase 2
- Status
- Recruiting
- Indication
- MASH
- Primary completion
- 4/1/2026
- Enrollment (planned/actual)
- 200
- Sponsor
- Altimmune
- Peptide
- Pemvidutide
Peptide under study
Pemvidutide
GLP-1 / glucagon dual agonist · Phase 2